[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0513862A - methods of treating ophthalmic conditions - Google Patents

methods of treating ophthalmic conditions

Info

Publication number
BRPI0513862A
BRPI0513862A BRPI0513862-0A BRPI0513862A BRPI0513862A BR PI0513862 A BRPI0513862 A BR PI0513862A BR PI0513862 A BRPI0513862 A BR PI0513862A BR PI0513862 A BRPI0513862 A BR PI0513862A
Authority
BR
Brazil
Prior art keywords
methods
therapeutic agents
ophthalmic conditions
treating ophthalmic
individual
Prior art date
Application number
BRPI0513862-0A
Other languages
Portuguese (pt)
Inventor
William A Hare
Elizabeth Wolde Mussie
Larry A Wheeler
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0513862A publication Critical patent/BRPI0513862A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MéTODOS DE TRATAR CONDIçõES OFTáLMICAS. Métodos de tratar condições oftálmicas incluem administrar um ou mais agentes terapêuticas a um indivíduo. Em um aspecto, um método inclui administrar um ou mais agentes terapêuticos de uma vez quando o indivíduo não está ciente de uma perda do campo visual associada com a condição oftálmica. Em outro aspecto, um método inclui administrar um ou mais agentes terapêuticas a um indivíduo com uma condição oftálmica associada com neurodegeneração retinal, em que a administração do agente terapêutico é eficaz na redução de uma diminuição em uma resposta do sistema nervoso central associada com a neurodegeneração retinal.METHODS OF TREATING Ophthalmic Conditions. Methods of treating ophthalmic conditions include administering one or more therapeutic agents to an individual. In one aspect, a method includes administering one or more therapeutic agents at a time when the subject is unaware of a visual field loss associated with the ophthalmic condition. In another aspect, a method includes administering one or more therapeutic agents to an individual with an ophthalmic condition associated with retinal neurodegeneration, wherein administration of the therapeutic agent is effective in reducing a decrease in a central nervous system response associated with neurodegeneration. retinal.

BRPI0513862-0A 2004-07-26 2005-07-26 methods of treating ophthalmic conditions BRPI0513862A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59142304P 2004-07-26 2004-07-26
PCT/US2005/026703 WO2006015075A1 (en) 2004-07-26 2005-07-26 Methods of treating ophthalmic conditions

Publications (1)

Publication Number Publication Date
BRPI0513862A true BRPI0513862A (en) 2008-05-20

Family

ID=35160080

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513862-0A BRPI0513862A (en) 2004-07-26 2005-07-26 methods of treating ophthalmic conditions

Country Status (6)

Country Link
EP (1) EP1776097A1 (en)
JP (1) JP2008507588A (en)
AU (1) AU2005269293A1 (en)
BR (1) BRPI0513862A (en)
CA (1) CA2575204A1 (en)
WO (1) WO2006015075A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
AU2010328186B2 (en) 2009-12-08 2014-12-18 Case Western Reserve University Compounds and methods of treating ocular disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
WO1997038691A1 (en) * 1996-04-17 1997-10-23 Sumitomo Pharmaceuticals Co., Ltd. Remedy for retinal neuropathy
CA2295098A1 (en) * 1997-06-30 1999-01-07 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
AU9797598A (en) * 1997-11-14 1999-06-07 Alcon Laboratories, Inc. Treatment of diabetic retinopathy
WO2000054810A1 (en) * 1999-03-12 2000-09-21 Alcon Laboratories, Inc Combination therapy for treating glaucoma
US20030119846A1 (en) * 2000-03-17 2003-06-26 Collier Jr Robert J. Compounds with 5-ht activity useful for controlling visual field loss
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
US6761694B2 (en) * 2001-12-13 2004-07-13 Allergan, Inc. Methods for measuring retinal damage
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers

Also Published As

Publication number Publication date
CA2575204A1 (en) 2006-02-09
AU2005269293A1 (en) 2006-02-09
WO2006015075A1 (en) 2006-02-09
EP1776097A1 (en) 2007-04-25
JP2008507588A (en) 2008-03-13

Similar Documents

Publication Publication Date Title
MX2022015499A (en) Methods of treating crohn's disease and ulcerative colitis.
AR044007A1 (en) METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
AR049985A1 (en) COMBINATION TREATMENT FOR NON-HEMATOLOGICAL MALIGNAL DISEASES
MY172012A (en) Use of dpp iv inhibitors
IL171607A (en) Use of a botulinum toxin for the preparation of a medicament for treating sinus headache
JOP20200156A1 (en) Esketamine for the treatment of depression
BR112016028964A2 (en) pd-1 and pd-11 antagonist treatment methods in combination with radiation therapy
BR112015001158A2 (en) ophthalmic formulation and its use and method for improving, reducing or treating presbyopia
AR109103A1 (en) TREATMENT OF FABRY'S DISEASE IN PATIENTS NOT TREATED AND PREVIOUSLY TREATED WITH ERT
AR043188A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF PROINFLAMATORY CYTOKINS
BR0308482A (en) Implantable drug delivery system
WO2010056302A3 (en) Iontophoretic therapeutic agent delivery system
WO2005051308A3 (en) Methods of treating diseases and disorders by targeting multiple kinases
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
MY175997A (en) Antl-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
WO2009068659A3 (en) Novel disease treatment by predicting drug association
WO2009073544A3 (en) Methods for treating a disorder by regulating gprc6a
PE20110711A1 (en) TREATMENT OF COGNITIVE DISORDERS WITH (R) -7-CHLORO-N- (QUINUCLIDIN-3-IL) BENZO [B] THIOPHENE-2-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
BR0313413A (en) Use of beta amyloid vaccination together with a selective cox-2 inhibitor for the treatment of alzheimer's disease
WO2005087210A3 (en) Prevention of retinopathy by inhibition of the visual cycle
BRPI0409699A (en) methods of inducing the diuretic effect, inducing, maintaining or restoring the diuretic effect of a non-adenosine modifying diuretic, maintaining, restoring or improving renal function in a patient, inducing diuresis, preventing the onset of renal impairment in a patient with fluid or CHF overload, treating CHF patients and improving overall health outcomes, pharmaceutical composition and uses
BRPI0513862A (en) methods of treating ophthalmic conditions
BR112012028652A2 (en) hydroxyalkylbenzylpyrazols and their use
MX2024010539A (en) Methods for treating diseases associated with ciliopathies.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired